Adalimumab for maintenance therapy for one year in Crohn's disease: Results of a Latin American single-center observational study;Adalimumabe na terapia de manutenção por um ano na doença de Crohn: Resultados de um estudo observacional unicêntrico Latinoamericano

Arquivos de Gastroenterologia

Volumn 51, Issue 1, 2014, Pages 39-45

  Kotze, Paulo Gustavo ^a   Abou Rejaile, Vinícius Rezende ^a   Uiema, Luciana Aparecida ^a   Olandoski, Marcia ^a   Sartor, Maria Cristina ^a   Miranda, Eron Fábio ^a   Kotze, Lorete Maria da Silva ^a   Saad Hossne, Rogério ^b  

^a PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adrenergic alpha antagonists, administration and dosage; Crohn disease, prevention and control; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; ARTICLE; CROHN DISEASE; DRUG EFFICACY; FEMALE; HUMAN; INFLAMMATORY BOWEL DISEASE; LONGITUDINAL STUDY; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; REMISSION; RETROSPECTIVE STUDY; SMOKING CESSATION; TELECONSULTATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CROHN DISEASE; FEMALE; HUMANS; INDUCTION CHEMOTHERAPY; LONGITUDINAL STUDIES; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84898884572     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/S0004-28032014000100009     Document Type: Article

References (26)

1. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology. 2006;130:650-6.
2. Brazilian Study Group of Inflammatory Bowel Diseases. Consensus guidelines for the management of inflammatory bowel disease. Arq Gastr. 2010;47:313-25.
3. Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci. 1989;34:1841-54.
4. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, LIchtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude J, Rutgeerts P, for the SONIC study group. Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease. N Engl J Med. 2010;362:1383-95.
5. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007;132:52-65.
6. D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, de Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, de Mierop FJ, Coche JR, van der Woude J, Ochsenkuhn T, van Bodegraven AA, Van Hootegem PP, Lambrecth GL, Mana F, Rutgeerts P, Feagan BG, Hommes D. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371:660.
7. Eugene C. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease. Clin Res Hepatol Gastroenterol. 2011;35:257-9.
8. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001;121:255-60.
9. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-9.
10. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323-33.
11. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514.
12. Kamm MA, Hanauer SB, Panaccione R, Colombel JF, Sandborn WJ, Pollack PF, Zhou Q, Robinson AM. Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease. Aliment Pharmacol Ther. 2011;34:306-17.
13. Kotze PG, Vieira A, Junior SCW, Salem JB, Kotze LMS. Adalimumab in the induction of Crohn's disease remission: results of a Brazilian multicenter case series. Rev Bras Coloproct. 2011;31:233-240.
14. Landi B, Anh TN, Cortot A, Soule JC, Rene E, Gendre JP, Bories P, See A, Metman EH, Florent C et al. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology. 1992;102:1647-53.
15. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:935-9.
16. Lofberg R, Louis EV, Reinisch W, Robinson AM, Kron M, Camez A, Pollack PF. Adalimumab Produces Clinical Remission and Reduces Extraintestinal Manifestations in Crohn's Disease: Results from CARE. Inflamm Bowel Dis. 2012;18:1-9.
17. Miheller P, Lakatos PL, Horváth G, Molnár T, Szamosi T, Czeglédi Z, Salamon A, Czimmer J, Rumi G, Palatka K, Papp M, Jakab Z, Szabó A, Gelley A, Lakatos L, Barta Z, Balázs C, Rácz I, Zeher M, Döbrönte Z, Altorjay I, Hunyady B, Simon L, Papp J, Banai J, Nagy F, Lonovics J, Ujszászy L, Muzes G, Herszényi L, Tulassay Z. Efficacy and safety of infliximab induction therapy in Crohn's Disease in Central Europe-a Hungarian nationwide observational study. BMC Gastroenterol. 2009;9:66.
18. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994;35:360-2.
19. Panaccione R, Loftus EV Jr, Binion D, McHugh K, Alam S, Chen N, Guerette B, Mulani P, Chao J. Efficacy and safety of adalimumab in Canadian patients with moderate to severe Crohn's disease: results of the adalimumab in Canadian subjects with moderate to severe Crohn's disease (ACCESS) trial. Can J Gastroenterol. 2011;25:419-25.
20. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-9.
21. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF. Adalimumab induction therapy for Crohn's Disease previously treated with infliximab. A Randomized trial. Ann Intern Med. 2007;146:829-38.
22. Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. Therap Adv Gastroenterol. 2011;4:375-89.
23. Steinhart AH, Ewe K, Griffiths AM, Modigliani R, Thomsen OO. Corticosteroids for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2003;4:CD000301.
24. Swoger JM, Loftus EV, Tremaine WJ, Faubion WA, Pardi DS, Kane SV, Hanson KA, Harmsen WS, Zinsmeister AR, Sandborn WJ. Adalimumab for Crohn's disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis. 2010;16:1912-21.
25. Teixeira FV, Hossne RS. Terapia biológica na doença inflamatória intestinal. In: Cardozo WS, Sobrado CW. Doença inflamatória intestinal. Barueri: Manole, 2012. p. 241-54.
26. Victoria CR, Sassak LY, Nunes HR. Incidence and prevalence rates of inflammatory bowel diseases, in midwestern São Paulo State, Brazil. Arq Gastr. 2009;46:20-5.